A case of renal injury induced by exposure to mercury-containing skin lightening cosmetics

Zhang Shuofan, Liu Yuqiu, Wu Min, Chen Sijie, Tang Rining, Pan Youwen, Zhang Xiaoliang, Liu Bicheng

PDF(1842 KB)
Chinese Journal of Nephrology ›› 2020, Vol. 36 ›› Issue (5) : 397-399. DOI: 10.3760/cma.j.cn441217-20191118-00075
Case Report

A case of renal injury induced by exposure to mercury-containing skin lightening cosmetics

Author information +
History +

Abstract

Cite this article

Download Citations
Zhang Shuofan. , Liu Yuqiu. , Wu Min. , Chen Sijie. , Tang Rining. , Pan Youwen. , Zhang Xiaoliang. , Liu Bicheng. A case of renal injury induced by exposure to mercury-containing skin lightening cosmetics[J]. Chinese Journal of Nephrology, 2020, 36(5): 397-399. DOI: 10.3760/cma.j.cn441217-20191118-00075.
患者,女,40岁,因“反复双下肢水肿3个月,加重4 d”于2018年9月3日入本院。患者3个月前无明显诱因下出现双下肢对称凹陷性水肿,晨轻暮重,休息或抬高下肢后减轻,伴双手麻木,未留意尿泡沫增多与否,无肉眼血尿,无尿量减少,未予重视。4 d前,患者感双下肢水肿加重,休息后无缓解,伴尿泡沫增多,无肉眼血尿,无恶心呕吐,无胸闷气促,外院查血生化示白蛋白28 g/L、尿蛋白量5 g/24 h(尿量1.443 L/24 h),诊断为“肾病综合征(NS)”,后至本院就诊。病程中,患者食纳、睡眠尚可,大便正常,体重无明显变化。平素体健,否认其他基础疾病。查体:体温 36.9℃,脉搏 72次/min,呼吸16次/min,血压125/85 mmHg,下颌可扪及数枚肿大淋巴结,大者约1 cm×1 cm,质韧,边界清,活动好,无压痛,舌体侧缘可见多个散在小溃疡(图1),双下肢轻度对称凹陷性水肿,余无特殊。查血生化示白蛋白降低、低密度脂蛋白升高,尿蛋白量 2.528 g/24 h(尿量1.700 L/24 h),血常规、病毒八项、血清肿瘤标志物、抗中性粒细胞胞质抗体、体液免疫特定蛋白、M蛋白分析、抗磷脂酶A2受体抗体、抗环瓜氨酸肽抗体、甲状腺功能未见异常,余实验室检查结果见表1。泌尿系统彩超示:左肾局部肾柱肥大可能,余未见明显异常。肾穿刺活检:(1)免疫荧光染色:肾小球系膜区IgA(2+~3+)(图2A)、IgM(2+)、C3(±)颗粒状沉积。(2)光镜:33个肾小球,系膜细胞和基质轻度局灶节段性增生,内皮细胞未见增生,毛细血管袢开放良好。PASM染色显示毛细血管基底膜无明显增厚,节段空泡变性,系膜区见少量嗜复红蛋白沉积(图2C)。肾小管未见萎缩,小管上皮细胞颗粒变性,部分肾小管上皮细胞低平,刷状缘脱落,管腔见红细胞和少量蛋白颗粒。肾间质轻度水肿,灶性纤维结缔组织增生,未见炎性细胞浸润。细小动脉壁平滑肌空泡变性。见图2B图2C图2D。(3)电镜: 1个肾小球,系膜区电子致密物沉积极少(图2E箭头示),系膜细胞和基质轻度增生,基底膜厚度336~389 nm,节段内疏松层增厚,袢腔内见红细胞。内皮细胞肿胀。足细胞肿胀伴空泡变性,偶见脂滴,足突广泛融合,微绒毛增多。肾小管未见萎缩,近曲小管腔面侧见密集且细长的微绒毛。肾间质未见炎性细胞浸润和纤维组织增生。见图2E图2F。结合病史及实验室检查,诊断为:肾病综合征;肾小球微小病变伴IgA沉积。
图1 舌体侧缘多个散在小溃疡

Full size|PPT slide

表1 入院实验室检查结果
检查指标 结果 参考值
总蛋白(g/L) 50.6↓ 65.0~85.0
白蛋白(g/L) 25.1↓ 40.0~55.0
血肌酐(μmol/L) 45↓ 57~97
胆碱酯酶(IU/L) 15 733↑ 5 000~12 000
低密度脂蛋白(mmol/L) 7.99↑ 0~3.12
血钙(mmol/L) 2.02↓ 2.11~2.52
血磷(mmol/L) 1.59↑ 0.80~1.50
D-二聚体(g/L) 588↑ 0~500
纤维蛋白原(g/L) 4.25↑ 2.00~4.00
红细胞沉降率(mm/h) 36↑ 0~15
抗核抗体 1∶100 阴性
尿蛋白 3+ 阴性
尿隐血 1+ 阴性
尿红细胞(万/ml) 5.45 0~24.00
尿红细胞形态 多形型 阴性
24 h尿蛋白量(g) 2.528↑ 0.028~0.141
尿NAG(U/L) 18.6↑ 0~12.0
尿β2微球蛋白(mg/L) 0.825↑ 0~0.200
尿α1微球蛋白(mg/L) 12.2↑ 0~12.0
尿转铁蛋白(mg/L) 47.7↑ 0~2.2
尿IgG(mg/L) 49.6↑ 0~9.6
图2 患者肾穿刺活检病理结果
注:A:免疫荧光染色 ×200;B:PAS染色 ×40;C:PASM染色 ×400;D:Masson染色 ×40;E:电镜 ×3 000;F:电镜 ×2 500

Full size|PPT slide

诊治的过程中,我们发现患者皮肤与健康人相比异常白皙,遂追问病史。患者6个月前使用美白化妆品后出现下颌及颈部疼痛,伴散在硬结,触之有痛感;有舌部溃疡,伴口内金属味、面部脱皮,偶有手指不自主震颤,有腰酸,无腰痛,无尿量减少、肉眼血尿,无下肢水肿,无眼睑震颤、齿龈肿痛,无头晕头痛,无恶心呕吐,无畏寒发热,曾至当地医院查血常规示白细胞计数正常,中性粒细胞比率 94.3%,予“头孢类抗生素(具体不详)”抗感染治疗14 d。后自行停用上述化妆品,症状减轻,面部脱皮现象渐止,脱皮后皮肤明显增白(图3),仍反复感下颌及颈部疼痛。考虑患者存在重金属中毒,遂送检尿液,查尿汞/尿肌酐比值31.7 μg/g(参考值0~4 μg/g),血铅、尿铅无异常。修正诊断为:(1)继发性肾病综合征、慢性汞中毒(中度中毒);(2)肾小球微小病变伴IgA沉积;(3)慢性肾脏病G1A3期(肾小球滤过率分级G1期,白蛋白尿分级A3期)。
图3 使用美白化妆品前后面部肤色对比
注:A:使用前;B:使用后

Full size|PPT slide

入院7 d后(2018年9月10日)开始行驱汞治疗,予肌肉注射二巯基丙磺酸钠 0.25 g/d,用药3 d停用4 d为1个疗程,共计4个疗程,并予口服美卓乐24 mg/d(9月8日至15日共使用8 d),辅以水化、保肾等治疗。接受驱汞治疗后患者尿汞排泄增加,尿蛋白量、尿汞/尿肌酐比值(排汞前31.7 μg/g,第1次排汞后270.0 μg/g,第2次排汞后240.0 μg/g)逐渐下降,血白蛋白水平升高。出院后随访12个月,患者经驱汞治疗后完全缓解,未再出现水肿、尿泡沫增多、淋巴结肿大及舌部溃疡等症状。
讨论 本例患者以NS为主要临床表现,伴有镜下血尿及肾小管损害,肾穿刺活检示肾小球微小病变伴IgA沉积,病史及实验室检查未提示继发性因素,似乎符合原发性NS的诊断。但追问病史后,明确该患者6个月前有美白化妆品使用史,出现面部皮肤脱屑、增白,3个月前出现乏力、腰酸、口内金属味、舌部溃疡、双手麻木、面颈部淋巴结肿痛等临床表现,送检尿液后提示尿汞显著升高,予驱汞治疗后NS完全缓解,确诊为汞中毒所致的伴IgA沉积的微小病变肾病(MCD-IgA)。
汞是具有肾毒性的重金属,对肾脏造成损害的主要是无机汞。无机汞以化合物形式存在,主要经消化道吸收,也可经皮肤吸收,在肾脏中浓度最高;化妆品中的汞以无机汞为主,长期使用可引起汞过量吸收导致汞中毒[1]。进入人体的汞约80%蓄积于肾脏,当汞的蓄积量超过肾脏自我解毒能力时即可引起肾损害[2]。慢性汞中毒引起的肾损害常表现为免疫复合物性肾小球肾炎,有NS、血尿等临床表现,可同时出现包括口唇、鼻、四肢远端感觉异常,意向性震颤,口腔内金属味、牙龈肿痛、牙龈蓝黑色汞线,头晕头痛,乏力纳差,恶心呕吐,咳嗽咳痰等多种肾外表现[3-5]。尿汞是临床反映汞接触最常用的指标[5]
膜性肾病(MN)是汞中毒引起的NS最常见的病理特征,其次为微小病变肾病(MCD),而局灶节段性肾小球硬化及IgA肾病(IgAN)较为少见[6]。当成年女性肾活检病理表现为MCD、儿童表现为MN时应警惕汞中毒的发生[6-7]。汞中毒相关NS的病理中,IgAN合并MCD曾被报道。与本案例不同的是,这些案例的电镜结果均可见明显的系膜区电子致密物沉积[8-9]。本例患者虽然尿隐血+,但尿红细胞计数在正常范围内,镜下血尿不明显,不符合IgA肾病的临床表现,结合病理更倾向于MCD的诊断。目前对于该病理类型属于MCD或IgAN的特殊类型还是MCD同时合并IgAN仍有争议,更多的证据认为MCD-IgA中的无血尿病例可能是MCD伴IgA非特异沉积[10]
治疗汞中毒相关NS首先应停止接触汞,同时可以使用螯合法进行驱汞治疗。在螯合剂的选择上,水溶性的二巯基丙磺酸钠、二巯基丁二酸钠因其良好的耐受性和疗效相较于D-青霉胺更优,但最佳治疗剂量仍需进一步研究[11]。本例患者口服类固醇激素2 d后即开始驱汞治疗,1周后再未服用激素,随访12个月,NS完全缓解,考虑激素与尿蛋白量的下降大概率无关。因此,对于汞中毒相关NS患者,我们建议在停止汞接触的前提下,首选驱汞治疗,若治疗无效或效果欠佳,可考虑联合类固醇激素治疗。汞中毒相关NS患者经过及时且正确的治疗可以完全康复。
汞中毒相关性肾损害的临床和病理特征与原发性肾小球疾病基本一致。由于我国仍在广泛使用含汞化合物,因此,临床医生在接诊患者时应考虑到汞中毒相关性肾损害发生的可能性,并重视问诊和查体,对可疑患者进行尿液检查。一旦确诊,患者应以停止汞接触、驱汞治疗为主,若驱汞治疗无效或效果欠佳,可联合使用类固醇激素。

References

[1]
王汉斌, 刘晓玲, 王海燕. 提高对生活接触致汞中毒相关性肾病的进一步认识[J]. 中国医刊, 2011, 46(7): 3-4. DOI: 10.3969/j.issn.1008-1070.2011.07.001.
[2]
Bridges CC, Bauch C, Verrey F, et al. Mercuric conjugates of cysteine are transported by the amino acid transporter system b(0,+): implications of molecular mimicry[J]. J Am Soc Nephrol, 2004, 15(3): 663-673. DOI: 10.1097/01.asn.0000113553.62380.f5.
Humans and other mammals continue to be exposed to various forms of mercury in the environment. The kidneys, specifically the epithelial cells lining the proximal tubules, are the primary targets where mercuric ions accumulate and exert their toxic effects. Although the actual mechanisms involved in the transport of mercuric ions along the proximal tubule have not been defined, current evidence implicates mercuric conjugates of cysteine, primarily 2-amino-3-(2-amino-2-carboxyethylsulfanylmercuricsulfanyl)propionic acid (Cys-S-Hg-S-Cys), as the most likely transportable species of inorganic mercury (Hg(2+)). Because Cys-S-Hg-S-Cys and the amino acid cystine (Cys-S-S-Cys) are structurally similar, it was hypothesized that Cys-S-Hg-S-Cys might act as a molecular mimic of cystine at one or more of the amino acid transporters involved in the luminal absorption of this amino acid. One such candidate is the Na(+)-independent heterodimeric transporter system b(0,+). Therefore, the transport of Cys-S-Hg-S-Cys and cystine was studied in MDCK II cells that were or were not stably transfected with b(0,+)AT-rBAT. Transport of Cys-S-Hg-S-Cys and cystine across the luminal plasma membrane was similar in the transfected cells, indicating that Cys-S-Hg-S-Cys can behave as a molecular mimic of cystine at the site of system b(0,+). Moreover, only the b(0,+)AT-rBAT transfectants became selectively intoxicated during exposure to Cys-S-Hg-S-Cys. These findings indicate that system b(0,+) likely contributes to the nephropathy induced by Hg(2+) in vivo. These data represent the first direct molecular evidence for the participation of a specific transporter in the luminal uptake of a large divalent metal cation in proximal tubular cells.
[3]
刘晓玲, 王汉斌. 汞中毒相关性肾损害[J]. 中国医刊, 2012, 47(2): 17-19. DOI: 10.3969/j.issn.1008-1070.2012.02.005.
[4]
Clarkson TW, Magos L, Myers GJ. The toxicology of mercury--current exposures and clinical manifestations[J]. N Engl J Med, 2003, 349(18): 1731-1737. DOI: 10.1056/NEJMra022471.
[5]
中华人民共和国卫生部. GBZ 89-2007职业性汞中毒诊断标准[S]. 北京: 人民卫生出版社, 2007.
[6]
秦爱博, 周福德, 赵明辉. 汞中毒相关性肾小球疾病的诊治进展[J]. 中华内科杂志, 2016, 55(12): 973-975. DOI: 10.3760/cma.j.issn.0578-1426.2016.12.016.
[7]
Onwuzuligbo O, Hendricks AR, Hassler J, et al. Mercury intoxication as a rare cause of membranous nephropathy in a child[J]. Am J Kidney Dis, 2018, 72(4): 601-605. DOI: 10.1053/j.ajkd.2018.05.013.
In adults, membranous nephropathy is the second most common cause of nephrotic syndrome. In contrast, minimal change disease and focal segmental glomerulosclerosis constitute the most common forms of nephrotic syndrome in children, while membranous nephropathy accounts for <5% of cases. In adults, causes of membranous nephropathy include autoantibodies directed against phospholipase A receptor and thrombospondin type 1 containing 7A, various infections, environmental toxicities, autoimmune disorders, malignancies, and other secondary forms. The most common causes of secondary membranous nephropathy in children are infections, autoimmune diseases, and neoplasia. We discuss an unusual presentation of new-onset membranous nephropathy due to mercury toxicity in a 14-year-old male with reflux nephropathy. This case underscores the importance of a high index of suspicion for uncommon causes of nephrotic syndrome in pediatric patients with membranous nephropathy.Copyright © 2018 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
[8]
Tang HL, Mak YF, Chu KH, et al. Minimal change disease caused by exposure to mercury-containing skin lightening cream: a report of 4 cases[J]. Clin Nephrol, 2013, 79(4): 326-329.
[9]
Niu HX, Li SH, Li HY, et al. Clinicopathological features, diagnosis, and treatment of IgA nephropathy with minimal change disease related to exposure to mercury-containing cosmetics: a case report[J]. Clin Nephrol, 2017, 87(2017)(4): 196-201. DOI: 10.5414/CN108967.
[10]
赵三龙, 赵非, 朱春华, 等. 伴IgA沉积的儿童微小病变肾病的临床病理特征及预后[J]. 中华实用儿科临床杂志, 2018, 33(5): 353-357. DOI: 10.3760/cma.j.issn.2095-428X.2018.05.008.
[11]
Chan T, Chan A, Tang HL. Nephrotic syndrome caused by exposures to skin-lightening cosmetic products containing inorganic mercury[J]. Clin Toxicol (Phila), 2020, 58(1): 9-15. DOI: 10.1080/15563650.2019.1639724.
PDF(1842 KB)

1028

Accesses

0

Citation

Detail

Sections
Recommended

/